Psychedelic Institute of Mental Health & Family Therapy
Psychedelic Institute of Mental Health & Family Therapy
Telehealth Ketamine Therapists
⌘K
Contact
Psychedelic Institute of Mental Health & Family Therapy
ketamine

Ketamine Reduces Suicidality-Associated Emergency Department Utilization in Patients With Treatment-Resistant Depression: A 6-Month Mirror-Image Study (Patarroyo-Rodriguez, et al, 2025)

La ketamina reduce la utilización del departamento de emergencias asociada a la suicidabilidad en pacientes con depresión resistente al tratamiento: un estudio de imagen especular de 6 meses
Michael DeMarco, PhD

by Michael DeMarco, PhD

Ketamine Reduces Suicidality-Associated Emergency Department Utilization in Patients With Treatment-Resistant Depression: A 6-Month Mirror-Image Study - PubMed
<span><b>Background:</b> Short-term studies have demonstrated antisuicidal effects of ketamine/esketamine for patients with treatment-resistant depression (TRD). However, long-term data and their impact in reducing suicidality-related health care utilization are limited. This 6-month mirror-image study co</span> …
PubMedLiliana Patarroyo-Rodriguez

(2025): "The cohort was 69% female, with a median age of 48.9 years; 97% had major depressive disorder, and most (75%) received IV ketamine. After the acute treatment phase, ED visits for suicidal ideation decreased by 84% (IRR=0.16, 95% CI, 0.06-0.46, P=.001), and total ED visits for suicidality decreased by 63% (IRR=0.37, 95% CI, 0.18-0.77, P=.007)."

"La cohorte era del 69% de mujeres, con una mediana de edad de 48,9 años; el 97% tenía trastorno depresivo mayor, y la mayoría (75%) recibía ketamina intravenosa. Después de la fase de tratamiento agudo, las visitas de disfunción eréctil para la ideación suicida disminuyeron en un 84% (IRR=0,16, 95% IC, 0,06-0,46, p=0,001) y las visitas totales de DE para la suicidio disminuyeron en un 63%"

More like this

Ketamine/esketamine in the treatment of depression with comorbid borderline personality disorder or traits: A systematic review of effectiveness (Scott, et al, 2025)

"patients with depression and comorbid borderline personality disorder/traits were equally likely to respond to ketamine/esketamine as those with depression but without borderline personality disorder/traits."
Exploring the Therapeutic Potential of Ketamine and Psilocybin in Comparison to Current Treatment Regimens for Treatment-Resistant Depression, Mood Disorders, and Post-traumatic Stress Disorder in the Pediatric Population (Hughes, et al, 2025)

Exploring the Therapeutic Potential of Ketamine and Psilocybin in Comparison to Current Treatment Regimens for Treatment-Resistant Depression, Mood Disorders, and Post-traumatic Stress Disorder in the Pediatric Population (Hughes, et al, 2025)

"Ketamine's use for pediatric TRD demonstrated rapid-onset relief for signs and symptoms of depression in children and adolescents, and psilocybin also decreased symptoms in patients with longstanding or refractory depression. Ketamine has been well tolerated and exhibited symptom improvements"
Psychedelics and mental health: reimagining care through science, insight, and compassion (Mikellides, et al, 2025)

Psychedelics and mental health: reimagining care through science, insight, and compassion (Mikellides, et al, 2025)

"These substances are not stand-alone medications; rather, they function as adjuncts to intensive psychotherapeutic processes. Training therapists and establishing ethical, evidence-based protocols is essential."
Mindfulness, music, visual occlusion in ketamine therapy for depression: do they change outcomes? A qualitative and quantitative analysis of a randomized controlled trial (Kheirkhah, et al, 2025)

Mindfulness, music, visual occlusion in ketamine therapy for depression: do they change outcomes? A qualitative and quantitative analysis of a randomized controlled trial (Kheirkhah, et al, 2025)

"...participants in the combined sensory intervention group reported deeper engagement, a stronger sense of connection to reality, increased focus on the experience..., moments of relief from sadness, and feelings of awe and spiritual insight compared to the control group. "
Vascular endothelial growth factor: a key factor in the onset and treatment of depression (Wang, et al, 2025)

Vascular endothelial growth factor: a key factor in the onset and treatment of depression (Wang, et al, 2025)

Factor de crecimiento endotelial vascular: un factor clave en la aparición y tratamiento de la depresión

Spotlight: Large responses to antidepressants or methodological artifacts? A secondary analysis of STAR∗D, a single-arm, open-label, nonindustry antidepressant trial (Xu, et al, 2025)

"...our results do not support the notion that a subgroup of patients with a large response exists. Instead, these findings support the assumption that the putative subgroups from industry randomized controlled trials may be artifacts caused by methodological biases."
Mastodon Mastodon